Role of Surgery in Patients with Stage IE Primary Thyroid MALT Lymphoma Staged by a Modified Classification System: The Tokyo Classification

Author:

Saito Yoshiyuki1ORCID,Watanabe Natsuko2,Suzuki Nami2ORCID,Saito Naoko3,Narimatsu Hiroto45ORCID,Takami Hiroshi1,Kameyama Kaori6ORCID,Yoshioka Kana1,Masaki Chie1,Akaishi Junko1,Hames Kiyomi Yamada1,Matsumoto Masako2,Fukushita Miho2,Yoshihara Ai2,Okamura Ritsuko1,Tomoda Chisato1,Suzuki Akifumi1,Matsuzu Kenichi1,Kitagawa Wataru1,Nagahama Mitsuji1,Noh Jaeduk Yoshimura2,Sugino Kiminori1,Ito Koichi1

Affiliation:

1. Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan

2. Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan

3. Department of Radiology, Juntendo University, Tokyo 113-8431, Japan

4. Cancer Prevention and Control Division, Kanagawa Cancer Center, Yokohama 241-8515, Japan

5. Graduate School of Health Innovation, Kanagawa University of Human Services, Kawasaki 238-8522, Japan

6. Department of Pathology, Showa University Northern Yokohama Hospital, Yokohama 224-8503, Japan

Abstract

Purposes: To establish the appropriate staging system and assess the role of curative thyroidectomy alone (Surgery) vs. involved-site radiation therapy after open biopsy (OB-ISRT) in stage IE mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: We examined the Tokyo Classification as a modified classification. This retrospective cohort study included 256 patients with thyroid MALT lymphoma; 137 underwent standard therapy (i.e., OB-ISRT) and were enrolled for the Tokyo classification. Sixty stage IE patients with the same diagnosis were examined to compare Surgery with OB-ISRT. Results: Overall survival (p = 0.0092) and relapse-free survival (0.00113) were significantly better in stage IE vs. stage IIE under the Tokyo classification. No OB-ISRT and Surgery patients died, but three OB-ISRT patients relapsed. The incidence of permanent complications was 28% in OB-ISRT (mainly dry mouth) and 0% in Surgery (p = 0.027). The number of painkiller prescription days was significantly greater in OB-ISRT (p < 0.001). During follow-up, the rate of the new appearance/change of the low-density area in the thyroid gland was significantly higher in OB-ISRT (p = 0.031). Conclusions: The Tokyo classification allows an appropriate discrimination between stages IE and IIE MALT lymphoma. Surgery can provide a good prognosis in stage IE cases; it also avoids complications, shortens painful periods during treatment, and simplifies ultrasound follow-up.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference23 articles.

1. Occurrence and prognosis of extranodal lymphomas;Freeman;Cancer,1972

2. Primary thyroid lymphoma: A clinical review;Stein;J. Clin. Endocrinol. Metab.,2013

3. Hashimoto thyroiditis in primary thyroid non-Hodgkin lymphoma: A systematic review and meta-analysis;Travaglino;Am. J. Clin. Pathol.,2020

4. Long-term outcomes of 107 cases of primary thyroid mucosa-associated lymphoid tissue lymphoma at a single medical institution in Japan;Watanabe;J. Clin. Endocrinol. Metab.,2018

5. Zelenetz, A., Gordon, L., Arbramson, J., Advani, R., Bartlett, N., Elizabeth Budde, L., and National Comprehensive Cancer Network (2022). NCCN clinical practice guidelines in oncology. B-cell lymphomas. Version 5.2022. J. Natl. Compr. Cancer Netw.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A Case of Primary Thyroid Maltoma;Korean Society of Head and Neck Oncology;2024-05-30

2. Primary thyroid MALT lymphoma with a probable brain secondary in a male patient: A case report;International Journal of Surgery Case Reports;2024-01

3. Mucosa-associated lymphoid tissue lymphoma of the thyroid gland: A case report;Asian Journal of Surgery;2023-12

4. Surgery is a Viable Treatment Option for Stage IE Primary Thyroid Lymphoma;Annals of Surgical Oncology;2023-11-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3